Cash receipts from customers Q2 FY23 were $8k, compared to $33k in Q1 FY23. The Company received a A$986,286 cash rebate from the Australian Federal Government’s R&D tax incentive program in relation to expenditure incurred on eligible R&D activities conducted in Australia in the 2021 fiscal year. The net cash used in G&A activities in the quarter was $734k compared to $595k in Q1 FY23. Payments to Related Parties, for the quarter includes $402k in payment of Non-Executive Director’s fees and Executive Director’s remuneration. The net cash used in R&D activities in the quarter was $5.87 million, compared to $7.17 million in Q1 FY23. The decrease was mainly due to a reduction in manufacturing activities during the quarter. Total net cash outflows used in operating activities in the quarter were $7.02 million compared to $6.35 million in Q1 FY23. Immutep’s cash and cash equivalent balance at 31 December 2022 was approximately $68.38 million, giving the Company an expected cash reach based on current estimates to the end of FY24. Immutep will continue to manage its strong cash balance carefully as it pursues its overall clinical development strategy.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IMMP:
- Immutep achieves 50% enrollment milestone in Phase IIB TACTI-003 trial
- Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer
- Immutep announces results of FDA meeting on eftilagimod alpha
- Immutep achieves commercial scale in manufacturing of eftilagimod alpha
- Immutep Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease
